Paricalcitol for reduction of albuminuria in diabetes [2]

The Lancet

Volumn 377, Issue 9766, 2011, Pages 635-

  Kassimatis, Theodoros ^a  

^a IASO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; PARICALCITOL; VITAMIN D RECEPTOR; BONE DENSITY CONSERVATION AGENT; ERGOCALCIFEROL;

ALBUMINURIA; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG SAFETY; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SIDE EFFECT; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG TOXICITY; KIDNEY FUNCTION TEST; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; URINE;

ALBUMINURIA; BONE DENSITY CONSERVATION AGENTS; CREATININE; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; ERGOCALCIFEROLS; HUMANS; KIDNEY FUNCTION TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79951800935     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60223-7     Document Type: Letter

References (1)

1. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-51.